Clinical comparison · Sexual wellness
PT-141 vs Oxytocin
PT-141 is a melanocortin agonist acting on arousal circuits. Oxytocin supports bonding and intimacy but is not a primary libido agent.
Attribute
PT-141
Oxytocin
Mechanism
Melanocortin MC3/MC4 receptor agonist acting centrally on sexual arousal pathways.
Neuropeptide; central bonding and prosocial signaling with peripheral smooth-muscle effects.
Standard dosing
1–2 mg SC 45 minutes before activity, max 8 doses/month.
10–40 IU sublingual or intranasal as needed.
Indications
- HSDD in women
- Erectile response adjunct in men
- Libido
- Intimacy and bonding
- Anxiety adjunct
- Sexual wellness protocols
Strengths
- Central mechanism independent of vascular pathway
- Works when PDE5 inhibitors fail
- Non-hormonal
- Rapid onset via intranasal route
Cautions
- Nausea, flushing
- Transient blood-pressure increase
- Avoid in uncontrolled hypertension
- Short duration
- Not a primary libido agent
FAQs
- Can PT-141 and oxytocin be used together?
- Yes. PT-141 45 minutes prior + intranasal oxytocin closer to activity is a common combined protocol.
- Which one works when PDE5 inhibitors fail?
- PT-141, because it acts centrally rather than through the vascular pathway.